Our lack of diagnostic precision with Computed Axial Tomography (CAT) scanning, Prostascint Scans and Positron Emitting Tomography (PET), are unable, in most cases, to state unequivocally whether a cancer is organ confined or not. This is expected to change dramatically with the addition of Magnetic Resonance Imaging Spectroscopy (MRIS) to our clinic. Using the HD-X 3.0 Tesla magnet with the software, our scanner promises to enhance our diagnostic capabilities immeasurably. For starters, the image quality provides 50% greater clarity of detail when compared to the commonly used 1.5 Tesla magnet. As I like to tell my patients, the difference in scan technique is all about the “S”. To restate, the “S” stands for Spectroscopy or the evaluation of cellular metabolic by products or metabolites including Citrate, Choline, Creatine, and Polyamines. The pattern of presentation, including ratios of the component metabolites, yields a “finger print” or cellular identity that predicts normalcy or lack of normalcy consistent with cancer.
Based on my years of research on prostatitis relevant to the benefit of the patented prostatitis formula Peenuts, I expect the signal received to have little to no artifact (noise), thereby, enhancing the interpretation of the scan performed. To state further, if inflammation associated with prostatitis is diminished or controlled for at the time of imaging, the signal represented will most accurately depict the true cellular characteristics allowing for an improved diagnosis. While MRI-S is already the most sensitive and specific diagnostic test available, the improved application and scan interpretation expects to negate unnecessary biopsies when the PSA is ≥ 1.0 ng/ml. Peter Scardino, M.D., Chairman of Urology and Surgery at Memorial Sloan Kettering (MSK) Cancer Center call MRI-S, the greatest diagnostic test that we have ever had for prostate cancer. The test is incredibly accurate, affordable and promises to change the diagnostic landscape for years and years to come.